Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ABL receives NIAID contract
Under the $102m contract, titled as "Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases", ABL will provide services from early feasibility studies through
Under the $102m contract, titled as "Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases", ABL will provide services from early feasibility studies through
The acquisition follows the previously announced asset purchase agreement. WBI-1001 is a non-steroidal, topical anti-inflammatory new chemical entity (NCE) agent, which has demonstrated efficacy and safety in Ph1
The treatment with oral, selective p38 inhibitor, resulted in a statistically significant reduction in pain over a 28-day period compared to placebo, as measured using the Western Ontario
The NIH exclusive license covers composition and uses of RCT1938 worldwide as a radiosensitizer to treat cancer and to treat or prevent radiation exposure in humans. RCT1938 is
The license agreement with Menarini include the commercialization of Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Priligy, which is indicated for the
According to the agreement, Oncobiologics will have access to XOMA’s diverse library of single-chain variable fragments antibodies and associated patent estate, and will utilize XOMA’s know-how and proven
The US patent no. 8,173,072 describes the conversion of nitrogen dioxide (NO2) to nitric oxide (NO), using the GeNO cartridge technology, in a gas stream to treat acute
The $336,793 funding from the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), an institute of the National Institutes of Health, represents the initial installment, with the
The collaboration leverages Anchor’s proprietary pepducin technology which provides an approach to studying the in vitro and in vivo biology of GPCRs and screening for small molecule modulators
ORP-100 is a recombinant engineered variant of thioredoxin, a human lung protein that has demonstrated in laboratory studies a potent ability to increase the fluidity of mucus. OrPro